Bad to the Bone

I just came across this excellent story by Mina Kimes, which gives a detailed chronicle of how the lines between physician discretion, off-label promotion, and human subjects research can be blurred by an aggressive manufacturer, in a context where life or death is on the line (bone cement used in spine surgery). ┬áThe article also suggests themes about medical malpractice, products liability, and physicians’ conflicts of interest too.

Be Sociable, Share!
This entry was posted in Christopher Robertson, FDA, First Amendment, Human Subjects Research, Liability by crobertson. Bookmark the permalink.

About crobertson

Christopher Robertson is a visiting professor at Harvard Law School (2013-2014), an associate professor at the James E. Rogers College of Law, University of Arizona, and a research associate with the Edmond J. Safra Center for Ethics at Harvard Law School. Professor Robertson graduated magna cum laude from Harvard Law School, where he also served as a fellow and lecturer. He earned a doctorate in Philosophy at Washington University in St. Louis, where he also taught bioethics. Robertson's research has been published in the Cornell Law Review, New York University Law Review, Emory Law Journal, Journal of Empirical Legal Studies, and the New England Journal of Medicine.